The nature of triple-negative breast cancer classification and antitumoral strategies
- Author:
Songmi KIM
1
;
Dong Hee KIM
;
Wooseok LEE
;
Yong-Moon LEE
;
Song-Yi CHOI
;
Kyudong HAN
Author Information
- Publication Type:Review article
- From:Genomics & Informatics 2020;18(4):e35-
- CountryRepublic of Korea
- Language:English
- Abstract: Identifying the patterns of gene expression in breast cancers is essential to understanding their pathophysiology and developing anticancer drugs. Breast cancer is a heterogeneous disease with different subtypes determined by distinct biological features. Luminal breast cancer is characterized by a relatively high expression of estrogen receptor (ER) and progesterone receptor (PR) genes, which are expressed in breast luminal cells. In ~25% of invasive breast cancers, human epidermal growth factor receptor 2 (HER2) is overexpressed; these cancers are categorized as the HER2 type. Triple-negative breast cancer (TNBC), in which the cancer cells do not express ER/PR or HER2, shows highly aggressive clinical outcomes. TNBC can be further classified into specific subtypes according to genomic mutations and cancer immunogenicity. Herein, we discuss the brief history of TNBC classification and its implications for promising treatments.
